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Background: Adjuvant treatment for pancreatic adenocarcinoma has been shown to improve survival.
An increasingly recognized ‘subtype’ of pancreatic adenocarcinoma is invasive intraductal papillary
mucinous neoplasm (IPMN). It is unclear whether adjuvant treatment for invasive IPMN improves survival.
This study aimed to determine the impact of adjuvant treatment in invasive IPMN.
Methods: We conducted a retrospective analysis of merged clinical databases including 412 patients
undergoing resection for IPMN at two academic institutions between 1989 and 2006.
Results: Of 412 patients with IPMN who underwent pancreatectomy, 98 had invasive carcinoma.
Median survival in invasive IPMN was 32 months. Adjuvant treatment did not affect median survival in
node-positive or node-negative invasive IPMN. Biopsy-proven recurrence of invasive IPMN occurred in
45 patients (46%). The median disease-free interval from resection to recurrence was 27 months.
Treatment of recurrences with chemotherapy or radiation therapy was not associated with a difference in
survival; however, a subgroup of patients with recurrence in the remnant pancreas who underwent
re-resection appeared to have more favourable outcomes.
Conclusions: An invasive component measuring >2 cm and lymph node involvement are associated
with poorer prognosis. Adjuvant therapy in invasive IPMN appears to confer no survival benefit. In
selected patients with recurrence of invasive IPMN in the remnant pancreas, re-resection should be
considered.
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Introduction
Intraductal papillary mucinous neoplasm (IPMN) of the pan-
creas has become a more commonly recognized neoplasm with
overt invasion or progression into invasive carcinoma. Prior
to the mid-1990s, IPMN had been reported under various
names and had often been misinterpreted as mucinous cystic
neoplasm, an entity now understood to be clearly distinct
from IPMN.1 Intraductal papillary mucinous neoplasm was
defined in 1996 by the World Health Organization (WHO)2 as a
mucin-producing cystic lesion with pancreatic ductal communi-
cation. These lesions are classified radiologically and pathologi-
cally by the type of pancreatic ductal involvement. Main duct
IPMN may involve the main duct exclusively (main-type IPMN)
or the main duct and side branch ducts (mixed-type IPMN).
Intraductal papillary mucinous neoplasms with exclusive
involvement of branch ducts are classified as branch-type IPMN.
The disease has variable malignant potential, but main duct
IPMN carries a significantly greater risk of malignancy than
IPMN with exclusively branch duct involvement according to
natural history studies and surgical series.3 Malignant potential
is graded pathologically by the degree of dysplasia or invasion
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(low grade, high grade, invasive); invasive IPMN confers a clearly
distinct poor prognosis.
A number of investigators have suggested that patients with
invasive IPMNmay have better survival than patients with pancre-
atic ductal adenocarcinoma (PDAC). Complicating this compari-
son, invasive IPMN presents more commonly at earlier stages
(stages I and II). Recently, investigators have examined matched
comparisons of these groups to address this question.4 Because
adjuvant treatment for PDAC has been shown to improve survival,
it is often recommended for patients with invasive IPMN, particu-
larly in cases with poor prognostic factors (e.g. positive lymph
nodes and/or positive surgical margins).5 Nonetheless, it is unclear
whether adjuvant treatment for invasive IPMN improves survival.
Moreover, no studies to date have demonstrated a significant
impact of adjuvant chemotherapy or chemoradiation in patients
who have undergone resection for invasive IPMN.We utilized two,
large, prospectively maintained databases from high-volume aca-
demic institutions with the aim of describing the characteristics of
patients with invasive IPMN, determining predictors of survival in
patients with invasive IPMN, and determining the impact of adju-
vant therapy on survival in invasive IPMN. Although this is a
retrospective study and therefore involves the potential pitfalls of
selection bias, our hypothesis was that adjuvant treatment, with
either chemotherapy or combination chemoradiation, would
improve survival in patients with invasive IPMN.
Materials and methods
Patient selection
From 1 January 1989 to 31 December 2006, 412 patients under-
went pancreatic resection for IPMN at Indiana University Hospi-
tal (Indianapolis, Indiana, n = 181) and Mayo Clinic (Rochester,
Minnesota, n = 231) (Fig. 1). Starting in 1989, patients were
accrued and entered prospectively into a clinical database
approved by both the Indiana University Institutional Review
Board and the Mayo Clinic Institutional Review Board. Patients
were staged by history and physical examination, serum
laboratory studies, chest radiography, dual-phase computed
tomography and magnetic resonance imaging. Endoscopic ultra-
sonography with fine-needle aspiration biopsy and/or main duct
brushing by endoscopic retrograde cholangiopancreatography
were used commonly to establish preoperative cytopathological
diagnoses. All resected IPMN were re-reviewed systematically
by pathologists experienced in the classification of IPMN.6 Based
on preoperative radiographic imaging, IPMN were classified
into three morphological subtypes comprising main, mixed and
branch duct variants. Based on surgical pathology, IPMN were
graded histologically as adenoma (n = 140), borderline neoplasm
(n = 124), carcinoma in situ (CIS) (n = 50) or invasive carcinoma
(invasive IPMN group, n = 98) according to the WHO classifica-
tion of IPMN.7 In the most recent classification, the adenoma and
borderline lesions are grouped as low grade and CIS is considered
high grade. These categories were defined collectively as non-
invasive IPMNs (non-invasive IPMN group, n = 314).
Surgery
For patients with invasive IPMN, resection consisted of pancre-
atoduodenectomy (PD) in 62 patients (63%) and distal pancre-
atectomy (DP) in 19 patients (20%). Seventeen patients (17%)
with multifocal IPMN or extensive main duct IPMN underwent
total pancreatectomy (TP). In the Mayo Clinic patients, extended
lymph node dissection was commonly performed with the aim
of eradicating residual cancer cells. Intraoperative frozen section
examination of the pancreatic surgical margins was performed
routinely. In the patients with positive margins (invasive IPMN or
CIS), additional resection was continued until an R0 resection
was obtained whenever possible. Inability to obtain a cancer-free
margin was denoted in the analysis. Tumour–node–metastasis
(TNM) staging was defined according to the sixth edition of the
American Joint Committee on Cancer (AJCC).
Adjuvant treatment
None of the patients in this study underwent neoadjuvant treat-
ment. Adjuvant treatment was employed most often in patients
with positive lymph nodes (stage IIB and above) and/or positive
surgical margins. According to performance status, adjuvant
treatment was typically delivered 4–8 weeks postoperatively. The
regimen of adjuvant treatment (chemotherapy, chemoradiation)
was selected according to the institution and the suggestions of the
oncologist. Agents including 5-fluorouracil (5-FU) and/or gem-
citabine were used for either adjuvant chemotherapy or chemo-
radiation. For gemcitabine chemotherapy, the typical regimen
involved 6 months of weekly intravenous infusion at 1000 mg/m2.
The 5-FU chemotherapy regimen varied widely during the period
of the study. A typical chemoradiation regimen involved 45 Gy
administered over 5 weeks and either 5-FU or gemcitabine
412 patients with
IPMNs
Non-invasive IPMN
n = 314
Invasive IPMN
n = 98
No adjuvant
treatment
n = 61
Stagel, IIA RO,
n = 47
Stagel IIB, IV, R1 or R2,
n = 14
Adjuvant treatment
n = 37
(chemotherapy, n = 7;
chemoradiation, n = 30)
Figure 1 Selection of patients with invasive intraductal papillary
mucinous neoplasm (IPMN)
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administered during the first and last weeks of radiotherapy.
Patients who did not complete the planned adjuvant therapy were
analysed on an intent-to-treat basis with their respective intended
treatment group.
Endpoints
Variables evaluated in this study included age, sex, symptoms/
conditions (pain, jaundice, weight loss, acute pancreatitis, chronic
pancreatitis), and preoperative serum CA 19-9 level. Preoperative
biopsies were graded as non-malignant or malignant (high-grade
atypia or adenocarcinoma). Pathological examination determined
tumour size (defined as maximum diameter), size of invasive
component, histological differentiation (good,moderate or poor),
margin of resection (positive or negative), node status (positive or
negative), number of examined nodes, metastases, and perineural
and perivascular invasion. Margins assessed included the pancre-
atic neck, bile duct, uncinate/retroperitoneal and duodenal in
patients undergoing PD. Recurrences were classified as locore-
gional, distant metastasis or carcinomatosis. Postoperative out-
comes were also assessed for duration of hospital stay, morbidity
and mortality.
Statistical analysis
Data analyses were carried out with GraphPad Prism (GraphPad
Software, Inc., La Jolla, CA, USA) and stata 10.0 (StataCorp LP,
College Station, TX, USA). Survival time was measured from the
date of operation until death or last follow-up (the censoring date
was 1 December 2008). Statistical associations between categorical
factors were assessed using Fisher’s exact test. The association of
categorical factors with survival (univariate analysis) was assessed
using the Kaplan–Meier method and was tested using the log-rank
test. Multivariate analyses were undertaken via Cox proportional
hazards regression and involved all preoperative factors, which
were significantly associated with survival as determined by
the univariable analysis. A stepwise model selection was used with
probability of entry into the model set at 0.10 and the probability
of a factor remaining in the model set at 0.20. Statistical signi-
ficance within the Cox model was tested using the Wald test.
Statistical significance was set at P < 0.05.
Results
Of 412 patients who underwent resection for IPMN, 98 (24%)
had a pathological diagnosis of invasive IPMN.
Characteristics of patients with invasive IPMN are summarized
in Table 1. The mean age of patients with invasive IPMN was
70 years. Male patients predominated. Overall, 90% of invasive
IPMN patients presented with symptoms or associated condi-
tions. Most commonly, patients presented with abdominal pain
(56%), but approximately one-third presented with jaundice
and/or weight loss. The majority (89%) of patients had pathologi-
cal main duct involvement (main- and mixed-types) IPMN.Main
duct dilation, however, was >1 cm in only 15% of patients. Of
the patients with branch-type IPMN (11%), approximately half
were multifocal (6%) vs. unifocal (5%). A little over half (53%)
of patients had documented mural nodules on cross-sectional
imaging or endoscopy prior to operation.
Intraductal papillary mucinous neoplasms were located more
commonly in the head than in the tail of the pancreas (62%
vs. 20%), but 18% of patients required total pancreatectomy to
achieve negative margins of resection. In addition, 10% of patients
also required superior mesenteric and/or portal venous resection
to achieve negative surgical margins. Patient duration of stay was
14.5 days, but varied considerably over the series. Patient morbid-
ity and 30-day or in-hospital mortality rates were 44% and 3%,
respectively.
The overall mean size of invasive IPMN was 4 cm. Mean sizes
in main, mixed and branch types were 6 cm, 3 cm and 4 cm,
Table 1 Characteristics of patients with invasive intraductal papillary
mucinous neoplasm (IPMN)
Invasive IPMN
Patients, n 98
Mean age, years 70
Sex ratio, male : female 1 : 5
Symptoms/conditions, n 87 (90%)
Abdominal pain, n 54 (56%)
Jaundice, n 33 (34%)
Weight loss, n 32 (33%)
Pancreatitis, n 23 (23%)
Operation
Pancreaticoduodenectomy, n 62 (62%)
Distal pancreatectomy, n 19 (20%)
Total pancreatectomy, n 17 (18%)
Duration of stay, days 14.5
Morbidity, n 43 (44%)
Mortality, n 3 (3%)
IPMN type
Main, n 41 (42%)
Mixed, n 47 (47%)
Branch, n 10 (11%)
Mean size, cm (range) 4 (0.9–10)
AJCC stage
I, n 36
IIA, n 16
IIB, n 45
III, n 0
IV, n 1
Margin +, n 9 (9%)
Perineural invasion +, n 47 (48%)
Perivascular invasion +, n 18 (18%)
AJCC, American Joint Committee on Cancer
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respectively. The mean size of the actual invasive component was
3 cm. Mean sizes of invasive components in main, mixed and
branch types were similar, at 4 cm, 3 cm and 3 cm, respectively. All
patients were at disease stages I or II, except for one patient,
who was at stage IV. This patient had a negative intraope-
rative liver biopsy, which, on permanent section, was read as
adenocarcinoma.
A total of 91% of patients underwent R0 resection, leaving
9% with a positive margin of invasive IPMN (R1). Lymph nodes
were positive in 46 (40%) patients, with 48% of the carcinomas
showing perineural invasion and 18% showing perivascular
invasion.
The mean follow-up in this combined series was 32 months
(range 12–180 months). Table 2 summarizes the univariate analy-
sis of preoperative factors (based on clinical examination and
radiological findings) influencing survival in the 98 patients with
invasive IPMN. Advanced age suggested a trend toward decreased
survival (P = 0.1), but jaundice, elevated serum CA 19-9, larger
IPMN, and the presence of mural nodules demonstrated no trend
toward decreased survival. Paradoxically, reported weight loss
was associated with increased survival (48 months vs. 24 months)
(P = 0.04).
Pathological findings
Larger size of invasive component, positive lymph node status,
positive margin status, poor tumour differentiation, and the pres-
ence of perineural or perivascular invasion were all factors which
correlated on univariate analysis with poorer survival (Table 3).
Overall median survival and 5-year survival rates in patients with
invasive IPMN undergoing resection were 32 months and 30%,
respectively.
Impact of adjuvant treatment
The characteristics of patients receiving adjuvant vs. no adjuvant
therapy are demonstrated in Table 4. Notably, the adjuvant group
had a larger mean size of neoplasm (4 cm vs. 3 cm) and larger
mean size of invasive component (3.5 cm vs. 2.5 cm) (P = 0.01),
greater rates of positive lymph nodes (65% vs. 26%) (P = 0.001),
and a greater incidence of involved margins (19% vs. 3%) (P =
0.02) than the group not receiving adjuvant therapy. No difference
in perioperative morbidity or mortality was noted between these
groups. Adjuvant therapy was achieved in 37 patients (37%)
and consisted of chemotherapy based on 5-FU in two cases,
gemcitabine-based chemotherapy in five and chemoradiation in
30 patients (four underwent gemcitabine-based chemotherapy
and 26 underwent 5-FU-based chemotherapy) (Fig. 1). Sixty-one
of 98 patients in the invasive IPMN group did not undergo any
adjuvant treatment. Of these 61 patients, 14 were at disease stage
IIB or higher and/or had positive surgical margins. Overall, the 37
patients who received adjuvant treatment had decreased 5-year
overall survival (22% vs. 36%; P = 0.002) and showed a trend
toward decreased median survival (23 months vs. 38 months;
95% confidence interval [CI] 0.36–1.03) compared with the 61
patients who did not receive adjuvant treatment (Table 4) (Fig. 2).
Patients with stage IIA or lower disease and a negative operative
margin who received (n = 5) or did not receive (n = 47) adju-
vant therapy demonstrated no difference in median survival
(63 months vs. 48 months; P = 0.98) (Fig. 3A). Patients with stage
IIB or higher disease and/or positive surgical margins who
received (n = 37) or did not receive (n = 14) adjuvant treatment
had similar median survival (17 months vs. 22 months; P = 0.67),
which suggests that the overall poorer survival with adjuvant
treatment may reflect a selection bias (Fig. 3B).
Table 2 Univariate analysis of preoperative factors (clinical examina-
tion, radiological staging) influencing survival in patients with inva-
sive intraductal papillary mucinous neoplasm (IPMN)
Median survival,
months (IQR)
P-valuea
Age
<75 years 35 (15–82) 0.10
75 years 28 (7–44)
Sex
Female 38 (11–79) 0.77
Male 28 (13–80)
Abdominal pain
Yes 35 (13–127) 0.16
No 21 (11–63)
Jaundice
Yes 23 (13–119) 0.48
No 35 (11–80)
Weight loss
Yes 48 (11–127) 0.04
No 24 (13–46)
CA 19-9 serum levels
37 IU/ml 46 (8–80) 0.64
>37 IU/ml 14 (11–37)
IPMN size
<3 cm 44 (15–80) 0.20
3 cm 21 (11–82)
IPMN type 0.21b
Main duct 33 (12–80) 0.12
Branch duct 37 (21–119) 0.08
Mixed (main duct) 30 (15–not defined) 0.08
Mixed (branch duct) 13 (5–38)
Mural nodule
Yes 22 (11–79) 0.22
No 38 (13–82)
aValues in bold are significant at P < 0.05
bOverall P-value. Subsequent P-values reflect the comparison between
each of main, branch and mixed (primarily main duct) carcinomas with
mixed (primarily branch duct) carcinomas
IQR, interquartile range
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Recurrence
Forty-five patients (46%) developed a biopsy-proven recurrence
of invasive IPMN. Of these recurrences, nine (20%) were carci-
nomatosis, 13 (29%) recurred locally and 18 (40%) recurred as
metastases, predominately to the liver (13 patients). The median
post-surgery, recurrence-free survival of patients was 27 months
(Fig. 4). Of the 45 patients who suffered recurrence, 19 had
received chemotherapy, including two who received concomitant
external beam radiation after recurrence had been identified.
Three patients with recurrent invasive cancer in the pancreatic
gland (at 11, 12 and 60 months after resection) were treated with
re-resection; two remained alive at 74 months and 120 months
follow-up, but one died of disease 37 months after the original
operation. Thirteen patients received no further therapy for recur-
rence and 10 received care after the diagnosis of recurrence
outwith the primary study institutions and thus information on
their treatment is lacking (Fig. 5). No difference in median sur-
vival (from the date of initial surgery) was found between the 19
patients in whom recurrences were treated by chemotherapy
or chemoradiation (13 months) and the 13 patients who did not
receive any further treatment (21 months) (P = 0.15). The few
patients who were able to undergo re-resection, however, experi-
enced an apparent survival advantage (P < 0.02).
Multivariate analysis
Given the above results, we attempted to construct a global model
of risk factors which, simultaneously, account for shorter survival
associated with invasive IPMN. In this analysis, we considered all
preoperative factors (age, weight loss and IPMN type) and histo-
pathological factors (maximal size of invasive IPMN component,
presence or absence of positive lymph nodes, final surgical margin
status, carcinoma grading [poorly differentiated/dedifferentiated
vs. well or moderately differentiated], presence or absence of
perineural and perivascular invasion) associated with increased
survival on univariate analysis. A stepwise Cox proportional
hazards model was carried out as described in the statistical
methods. Of the factors considered, weight loss, an invasive com-
ponent >2 cm, and the presence of positive lymph nodes were
related to shorter survival (P < 0.05) Table 5.
Discussion
The current approach to adjuvant therapy for invasive IPMN is
not standardized, predominately because data concerning efficacy
in IPMN are lacking. Oncologists may be reluctant to administer
adjuvant treatment to patients with invasive IPMN because there
is little evidence to suggest that this approach is helpful. More
commonly, others extrapolate their adjuvant treatment approach
from the data available for the more common PDAC. As our
experience with IPMN expands, it becomes evident that the
natural history and behaviour of invasive IPMN may be distinct
from that of PDAC. It is therefore uncertain whether the simple
extension of our findings in PDAC is warranted. This large, ret-
rospective, combined-institution study sought to determine the
characteristics of patients with invasive IPMN, the predictors of
poor prognosis, and the role of adjuvant therapy in patients with
invasive IPMN.
These findings suggest that invasive IPMN occurs typically
in elderly, symptomatic, male patients. These individuals most
commonly present with abdominal pain and often with weight
loss and jaundice. Abdominal pain is not a typical presenting
symptom in PDAC. Invasive IPMN predominantly (89%) involves
the main duct (main and mixed types), although the majority of
these (85%) occur with main duct dilation of <1 cm, suggesting
that a simple size cut-off alone may be inadequate in predicting
main duct involvement or the potential for invasive malignancy.
Table 3 Univariate analysis of pathological findings leading to poorer
survival in patients with invasive intraductal papillary mucinous neo-
plasm (IPMN)
Pathological findings Median survival,
months (IQR)
P-valuea
Invasive component 0.01
<2 cm 79 (30–not defined)
2 cm 22 (10–41)
Pathology determined IPMN type 0.54b
Main duct 33 (15–80) 0.12
Side branch 37 (10–not defined) 0.56
Mixed (main branch) 22 (11–63) 0.34
Mixed (side branch) 11 (2–not defined)
Lymph nodes <0.001
Involved 15 (10–33)
Not involved 41 (21–127)
Margins with invasive IPMN 0.09
Involved 15 (11–38)
Not involved 32 (12–82)
Perineural invasion 0.02
Yes 15 (10–41)
No 41 (23–80)
Perivascular invasion <0.001
Yes 11 (7–17)
No 41 (15–119)
Poorly/dedifferentiated <0.001
Yes 15 (10–35)
No 44 (22–119)
Adjuvant therapy
Yes 23 (11–48) 0.13
No 38 (12–119)
aValues in bold are significant at P < 0.05
bOverall P-value. Subsequent P-values reflect the comparison between
each of main, branch and mixed (primarily main duct) carcinomas with
mixed (primarily branch duct) carcinomas
IQR, interquartile range
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Our study corroborates existing data in the literature regarding
invasive IPMN related to lymph node status,8 margin status9 and
perineural or perivascular invasion as factors influencing
survival.10 However, on examining multivariate analysis of these
factors, only lymph node involvement reached the level of statisti-
cal significance. The relationship between the size of IPMN and
malignancy is less clear.11,12 Alternatively, the size of the invasive
component in patients with invasive IPMN is an important factor
in predicting survival outcome in this combined series.13 Serum
CA 19-9 level was not found to be a prognostic factor as it is
thought to be in PDAC.14 Paradoxically, weight loss actually
appeared onmultivariate analysis to confer a survival advantage in
this group,which is at oddswith findings for all IPMNas this factor
is invariably correlated with the presence of invasive disease. One
potential explanation for this observation may be that the weight
loss present in these patients is related to steatorrhea, nausea,
anorexia or pancreatitis associated with the mucin production of
the IPMN, whereas malignant weight loss is more typical of the
more common ductal adenocarcinoma.These symptomsmay lead
patients to seekmedical care earlier, thus instigating a lead timebias
that results in prolonged survival in this group.
Existing literature supports the finding that invasive IPMN has
a poor prognosis, although it is significantly better than that in
PDAC, with an overall 5-year survival of 30–42%.4,15,16 This runs
counter to findings from some earlier studies in this regard.17
Given these differences in behaviour, the question remains
whether patients with invasive IPMN, as in PDAC, may derive
benefit from adjuvant or neoadjuvant treatment. Neoadjuvant
approaches were not employed in this study, partly because of the
inability to accurately differentiate between high-grade dysplasia
(carcinoma in situ) and invasive IPMN preoperatively. Invasive
IPMN was diagnosed correctly in only 68% of patients who
underwent preoperative biopsies, and 20% of patients with
non-invasive IPMN were mistakenly considered to have invasive
IPMN.
An important aspect of examining the postoperative treatment
of invasive IPMN is the role of adjuvant chemotherapy or radia-
tion. It is well known that pancreatic surgery is characterized by
substantial postoperative morbidity rates approaching 50%.18 In
the case of PDAC, nearly 25% of patients who undergo PD do not
receive adjuvant treatment as a result of complicated postope-
rative courses.19 Similarly, in the present series, 14 (27%) patients
(with stage IIB or higher status or positive operative margins)
were not able to finish or receive adjuvant treatment.
With regard to all invasive IPMN, a notable decrease in 5-year
overall survival was noted in those patients who received any
Table 4 Pathological and perioperative characteristics of patients who did (n = 37) or did not (n = 61) receive adjuvant treatment
Adjuvant treatment No adjuvant treatment P-valuea
Median (IQR) Median (IQR)
n = 37 n = 61
Median invasive component size, cm (95% CI) 3.5 (2.3–5.0) 2.5 (1.1–4.0) 0.01
Lymph node involvement, % 65 25 <0.001
Positive margin, % 19 3 0.02
Tumour differentiation
Poor/dedifferentiated, n 20 (54%) 25 (42%) NS
Moderate 14 (38%) 31 (52%) NS
High, n 3 (9%) 4 (8%) NS
Multifocal IPMNs, n (%) 3 (5%) 3 (8%) NS
Morbidity, n (%) 16 (43%) 27 (44%) NS
5-year overall survival (95% CI) 22% (9–38) 36% (22–50) 0.002
aValues in bold are significant at P < 0.05
95% CI, 95% confidence interval; NS, not significant
Adjuvant therapy
No adjuvant therapy
0
0
50
100
25 12575 17550 150100
Months
S
ur
vi
va
l, 
%
200
Figure 2 The effect of adjuvant therapy on overall survival in all
stages of invasive intraductal papillary mucinous neoplasm
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adjuvant therapy. Clearly, differences in disease stage contribute
to the detrimental effect on survival seen in the adjuvant group.
When further divided into advanced (stage IIB or higher disease
or positive margins) or early (stage IIA or lower disease and nega-
tive margins) groups, no benefit was seen in patients receiving
adjuvant therapies in either median or overall survival.
Gemcitabine-based chemotherapy alone was utilized in only
14% of patients receiving adjuvant treatment. Interestingly, post-
operative chemoradiation was more common in this study than
single-agent chemotherapy. Chemoradiation has not proven to be
more effective than chemotherapy alone in the adjuvant setting for
PDAC.20 In the setting of a positive postoperative margin, chemo-
radiation may be reasonable as in PDAC, but the number of R1
resections in our series precluded an adequately powered analysis
of radiation specifically for positive margin status in the setting of
invasive IPMN.A number of patients received 5-FU-based chemo-
therapy inour study.Although this regimen is no longer commonly
employed for PDAC, it is notable that a recent European series
suggested that 5-FU-based chemotherapy in PDAC remains effec-
tive and should not necessarily be abandoned.21
Recurrence is an important endpoint after resection for invasive
IPMN. Just under half the patients in this series experienced an
invasive recurrence. Additionally, the presence or absence of adju-
vant chemotherapy or chemoradiation appeared to have no clear
effect on recurrence-free survival. Analysis of the pattern of recur-
rence in patients with invasive IPMN showed that most patients
with recurrence had distant recurrence in the form of either car-
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Figure 3 The effect of adjuvant chemotherapy or chemoradiation on
overall survival of patients with invasive intraductal papillary muci-
nous neoplasm in (A) stage IIA or lower disease and negative opera-
tive margin (n = 52) and (B) stage IIB and higher disease and positive
operative margin (n = 46)
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Figure 4 Recurrence-free survival with and without adjuvant therapy
following pancreatectomy for invasive intraductal papillary mucinous
neoplasm
Invasive IPMN
n = 98
Undetermined
therapy
n = 10
Chemotherapy (17) or
chemoradiation (2)
n = 19
No further therapy
n = 13
Re-resection
n = 3
Invasive IPMN
recurrence
n = 45
Figure 5 Treatment of patients who experienced recurrence of inva-
sive intraductal papillary mucinous neoplasm (IPMN)
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cinomatosis or remote organ metastases (60% of recurrences).
This tumour biology is consistent with the patterns of recurrence
demonstrated previously for PDAC.22 Interestingly, no patient in
this series was noted to develop recurrence of low or high grade
IPMN in the remnant gland, although 13 developed invasive
recurrence locally.
Given that nearly half of these patients will experience recur-
rence in either a locoregional or distant fashion, the approach to
these recurrences is critical. Although this analysis referred to
only a small subgroup, we observed that salvage treatment (che-
motherapy or chemoradiation) failed to improve survival in
patients with invasive recurrences compared with patients who
underwent no further therapy. Interestingly, the few patients
(n = 3, 7%) with recurrence who underwent re-resection appeared
to demonstrate increased survival relative to patients who under-
went chemotherapy, chemoradiation or no additional therapy,
although clearly these patients were amenable to re-operation as a
result of favourable tumour and patient characteristics.
Importantly, our study involved several substantial confound-
ing issues and limitations. Firstly, the small number of patients
with advanced disease who did not receive planned adjuvant
treatment (n = 14) precludes us from drawing strong statistical
conclusions about those who did receive adjuvant treatment. Sec-
ondly, patients received a number of different adjuvant treatment
protocols. This heterogeneous approach affects the statistical
power and confidence of conclusions in any one adjuvant treat-
ment subgroup. Much of the variability in the adjuvant approach
is accounted for by the long period encompassed in our series
(1989–2007). Additionally, there are apparent differences in those
patients who were selected for adjuvant therapy. As Table 4 shows,
significant differences in the size of the invasive component, posi-
tive margins, and the presence of lymph node metastases are
noted in the adjuvant therapy group. These factors would clearly
mitigate potential benefits present in this group and these data
must be interpreted with this in mind. Importantly, no differences
in morbidity or tumour histology were seen between the two
treatment groups.
Given the above limitations, it is important to note that any
retrospective analysis is not definitive with regard to whether to
employ or abandon adjuvant therapy. Rather, these findings call
into question the benefit added by the addition of these poten-
tially morbid treatments. Based on these findings, we feel that
therapy should be reserved for fit patients and that tumour his-
tology, stage (particularly node-positive and/or margin-positive
disease) and patient factors should be considered by the medical
oncologist and surgeon in combination, and that these patients
should be surveyed closely for evidence of recurrence and
response to therapy.
Conclusions
Factors associated with decreased survival in invasive IPMN
included an invasive component measuring >2 cm and lymph
node involvement. Preoperative weight loss appeared to be
inversely related to survival in this group. Although main
duct involvement is commonly correlated with invasive
cancer, a minority of main duct IPMN cases had a pancreatic
duct >1 cm in diameter. The addition of adjuvant treatment
demonstrated no clear benefit in patients with invasive IPMN
in either early- or later-stage disease; however, those patients
given adjuvant treatment tended to have more aggressive pathol-
ogy. Finally, re-operation for recurrence was associated with
substantial longterm survival in three patients with invasive
recurrence in the remnant pancreas in this series, and should
be considered for patients with local recurrence amenable to
re-resection.
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